SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 5, 2003; DOI 10.1182/blood-2002-11-3400. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-11-3400v1 102/6/1966    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Salcedo, R. Articles by Oppenheim, J. J. Search for Related Content PubMed PubMed Citation Articles by Salcedo, R. Articles by Oppenheim, J. J. Related Collections Hemostasis, Thrombosis, and Vascular Biology Chemokines, Cytokines, and Interleukins Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2003, Vol. 102, No. 6, pp. 1966-1977 CHEMOKINES Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells Rosalba Salcedo, Xia Zhang, Howard A. Young, Nelson Michael, Ken Wasserman, Wei-Hong Ma, Manuela Martins-Green, William J. Murphy, and Joost J. Oppenheim From the Laboratory of Molecular Immunoregulation, Laboratory of Experimental Immunology, Cancer Center Research, National Cancer Institute (NCI), Intramural Research Support Program, Science Applications International Corporation (SAIC), Frederick, MD; Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD; and the Department of Cell Biology and Neuroscience, University of California, Riverside. Stimulation of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) increases the expression of CXCR4 on endothelial cells, rendering these cells more responsive to stromal-derived factor 1 (SDF-1), an angiogenic CXC chemokine and unique ligand for CXCR4. Here, we show that prostaglandin E2 (PGE2) mediates the effects of bFGF and VEGF in up-regulating CXCR4 expression on human microvascular endothelial cells (HMECs). Forskolin or 3-isobutyl-1-methyl xanthine (IBMX), 2 inducers of adenylate cyclase, markedly enhanced, whereas cyclooxygenase (COX) inhibitors including aspirin, piroxicam, and NS398 markedly inhibited CXCR4 expression on HMECs. Furthermore, the ability of PGE2 to augment in vitro tubular formation in SDF-1 containing matrigel was inhibited completely by blocking CXCR4. Treatment of bFGF- or VEGF-stimulated HMECs with COX inhibitors blocked tubular formation by about 50% to 70%. Prostaglandin-induced human endothelial cell organization and subsequent vascularization can be inhibited to a greater extent by a neutralizing antibody to human CXCR4 in severe combined immunodeficient mice. Additionally, VEGF- and bFGF-induced angiogenesis in vivo was also inhibited by about 50% by NS-398 or piroxicam, and this inhibitory effect was accompanied by decreased expression of CXCR4 on murine endothelial cells. Consequently, by inducing CXCR4 expression, prostaglandin accounts for about 50% of the tubular formation in vitro and in vivo angiogenic effects of VEGF and bFGF. Moreover, augmentation of CXCR4 expression by VEGF, bFGF, and PGE2 involves stimulation of transcription factors binding to the Sp1-binding sites within the promoter region of the CXCR4 gene. These findings indicate that PGE2 is a mediator of VEGF- and bFGF-induced CXCR4-dependent neovessel assembly in vivo and show that angiogenic effects of PGE2 require CXCR4 expression. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-S. Lin, Y.-S. Chen, H.-S. Chiang, and M.-C. Ma Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization J. Physiol., December 1, 2008; 586(23): 5757 - 5769. [Abstract] [Full Text] [PDF] A. Alfranca, J. M. Lopez-Oliva, L. Genis, D. Lopez-Maderuelo, I. Mirones, D. Salvado, A. J. Quesada, A. G. Arroyo, and J. M. Redondo PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGF{beta}/Alk5 signaling pathway Blood, August 15, 2008; 112(4): 1120 - 1128. [Abstract] [Full Text] [PDF] F. Finetti, R. Solito, L. Morbidelli, A. Giachetti, M. Ziche, and S. Donnini Prostaglandin E2 Regulates Angiogenesis via Activation of Fibroblast Growth Factor Receptor-1 J. Biol. Chem., January 25, 2008; 283(4): 2139 - 2146. [Abstract] [Full Text] [PDF] M. Yamashita, T. Shinohara, S. Tsuji, Q. N. Myrvik, A. Nishiyama, R. A. Henriksen, and Y. Shibata Catalytically Inactive Cyclooxygenase 2 and Absence of Prostaglandin E2 Biosynthesis in Murine Peritoneal Macrophages following In Vivo Phagocytosis of Heat-Killed Mycobacterium bovis Bacillus Calmette-Guerin J. Immunol., November 15, 2007; 179(10): 7072 - 7078. [Abstract] [Full Text] [PDF] J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF] S. Jain, G. Chakraborty, and G. C. Kundu The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C {alpha}/c-Src/I{kappa}B Kinase {alpha}/{beta}-Dependent Prostate Tumor Progression and Angiogenesis. Cancer Res., July 1, 2006; 66(13): 6638 - 6648. [Abstract] [Full Text] [PDF] S.-W. Kim, H. Han, G.-T. Chae, S.-H. Lee, S. Bo, J.-H. Yoon, Y.-S. Lee, K.-S. Lee, H.-K. Park, and K.-S. Kang Successful Stem Cell Therapy Using Umbilical Cord Blood-Derived Multipotent Stem Cells for Buerger's Disease and Ischemic Limb Disease Animal Model Stem Cells, June 1, 2006; 24(6): 1620 - 1626. [Abstract] [Full Text] [PDF] A. Alfranca, M. A. Iniguez, M. Fresno, and J. M. Redondo Prostanoid signal transduction and gene expression in the endothelium: Role in cardiovascular diseases Cardiovasc Res, June 1, 2006; 70(3): 446 - 456. [Abstract] [Full Text] [PDF] A. Lee, J. Frischer, A. Serur, J. Huang, J.-O Bae, Z. N. Kornfield, L. Eljuga, C. J. Shawber, N. Feirt, M. Mansukhani, et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res., April 15, 2006; 66(8): 4378 - 4384. [Abstract] [Full Text] [PDF] P. Goichberg, A. Kalinkovich, N. Borodovsky, M. Tesio, I. Petit, A. Nagler, I. Hardan, and T. Lapidot cAMP-induced PKC{zeta} activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors Blood, February 1, 2006; 107(3): 870 - 879. [Abstract] [Full Text] [PDF] D Wang and R N DuBois PROSTAGLANDINS AND CANCER Gut, January 1, 2006; 55(1): 115 - 122. [Full Text] [PDF] M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF] N. Kawao, M. Nagataki, K. Nagasawa, S. Kubo, K. Cushing, T. Wada, F. Sekiguchi, S. Ichida, M. D. Hollenberg, W. K. MacNaughton, et al. Signal Transduction for Proteinase-Activated Receptor-2-Triggered Prostaglandin E2 Formation in Human Lung Epithelial Cells J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 576 - 589. [Abstract] [Full Text] [PDF] J.-E. Huh, E.-O. Lee, M.-S. Kim, K.-S. Kang, C.-H. Kim, B.-C. Cha, Y.-J. Surh, and S.-H. Kim Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways Carcinogenesis, August 1, 2005; 26(8): 1436 - 1445. [Abstract] [Full Text] [PDF] M. Murakami, S. Masuda, S. Shimbara, Y. Ishikawa, T. Ishii, and I. Kudo Cellular Distribution, Post-translational Modification, and Tumorigenic Potential of Human Group III Secreted Phospholipase A2 J. Biol. Chem., July 1, 2005; 280(26): 24987 - 24998. [Abstract] [Full Text] [PDF] M. Ladetto, S. Vallet, A. Trojan, M. Dell'Aquila, L. Monitillo, R. Rosato, L. Santo, D. Drandi, A. Bertola, P. Falco, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome Blood, June 15, 2005; 105(12): 4784 - 4791. [Abstract] [Full Text] [PDF] T. Ara, K. Tokoyoda, R. Okamoto, P. A. Koni, and T. Nagasawa The role of CXCL12 in the organ-specific process of artery formation Blood, April 15, 2005; 105(8): 3155 - 3161. [Abstract] [Full Text] [PDF] I. Kryczek, A. Lange, P. Mottram, X. Alvarez, P. Cheng, M. Hogan, L. Moons, S. Wei, L. Zou, V. Machelon, et al. CXCL12 and Vascular Endothelial Growth Factor Synergistically Induce Neoangiogenesis in Human Ovarian Cancers Cancer Res., January 15, 2005; 65(2): 465 - 472. [Abstract] [Full Text] [PDF] H. Jiang, A. S. Weyrich, G. A. Zimmerman, and T. M. McIntyre Endothelial Cell Confluence Regulates Cyclooxygenase-2 and Prostaglandin E2 Production That Modulate Motility J. Biol. Chem., December 31, 2004; 279(53): 55905 - 55913. [Abstract] [Full Text] [PDF] T Sakurai, K Tamura, and H Kogo Vascular endothelial growth factor increases messenger RNAs encoding cyclooxygenase-II and membrane-associated prostaglandin E synthase in rat luteal cells J. Endocrinol., December 1, 2004; 183(3): 527 - 533. [Abstract] [Full Text] [PDF] J. Heidemann, H. Ogawa, P. Rafiee, N. Lugering, C. Maaser, W. Domschke, D. G. Binion, and M. B. Dwinell Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells Am J Physiol Gastrointest Liver Physiol, June 1, 2004; 286(6): G1059 - G1068. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020